English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
News
Honouring excellence in CML: Nominate for the 2026 iCMLf Prizes
December 2025 - Each year, we honour exceptional achievements in CML research and management by recognising lifetime contributions through the three iCMLf Prizes. Since their introduction, these awards have celebrated the work of remarkable scientists, clinicians, and advocates whose leadership, innovation, and dedication have shaped the global CML landscape.
We invite you once again to participate in this tradition by nominating outstanding individuals whose work has transformed our understanding of CML biology, advanced patient management, or improved access to treatment worldwide. Let’s spotlight the visionaries whose contributions continue to inspire the global CML community.
Session Summaries from the 67th ASH Annual Meeting
December 2025 - We're bringing you highlights from the 67th ASH Annual Meeting with a summary of selected scientific sessions on CML, a prospective study testing nilotinib vs. imatinib with early switch to improve TFR, and the first prospective trial of asciminib with dose escalation as second-line therapy.
🌟 Oral Abstract Session: CML clinical & epidemiological - Therapeutic agents to enhance patient outcomes
Chairs: Elisabetta Abruzzese (Rome) - Vivian Oehler (Seattle)
This clinical session presented major advances in novel TKIs, frontline optimisation strategies, real-world outcomes in blast-phase CML, and next-generation approaches to achieving deeper and safer molecular responses. Across six presentations, investigators showcased: promising phase 1 data for TERN-701 and TGRX-678, updated results from a frontline asciminib combination trial, the largest US analysis of blast-phase management, a prospectie study testing nilotinib vs. imatinib with early switch to improve TFR, and the first prospective trial of asciminib with dose escalation as second-line therapy.
Collectively, the studies demonstrated:
- High efficacy and favourable safety of new agents even in heavily pretreated or T315I-mutated patients,
- Asciminib’s expanding role in both frontline combinations and second-line therapy,
- The persistent challenge and therapeutic needs of blast-phase CML,
- The importance of risk-adapted frontline selection to improve long-term TFR outcomes,
- And the feasibility of dose escalation strategies with asciminib to address suboptimal responders.
Our key takeaways from the presentations:
Getting ready for ASH 2025 - Plan your CML Sessions
November 2025 - Only a few weeks to go until the 67th Annual Meeting of the American Society of Hematology (ASH). This year, the meeting takes place in Orlando, Florida, and online from 6th-9th December.
With a record-breaking number of abstracts submitted and more than 8,200 accepted, this premier event in hematology promises a wealth of exciting updates – including many important new insights into CML.
To help you plan your schedule, we have compiled a list of key CML sessions. These include an Education Spotlight Session, Oral Abstract Presentations, Poster sessions, and a Friday Satellite Symposium.
Don’t miss the annual iCMLf Forum and the oral presentation of the iCMLf/HARMONY Foundation CML Genomics project among this year’s highlights at ASH.
Have a question or suggestion for the iCMLf? The iCMLf’s Chief Executive, Nicola Evans will be on-site in Orlando. If you’d like to arrange a meeting, please contact us at info@cml-foundation.org.
We look forward to connecting with you at ASH 2025.
Reflecting on 2025 and Looking Ahead
As 2025 draws to a close, we look back on another year defined by collaboration, scientific progress, and a shared global commitment to improving outcomes for people living with CML. Across continents and clinical contexts, our community came together to learn, connect, and drive forward expert care.
iCMLf Forum - Saudi Arabia: Advancing CML Practice Through Global Collaboration
The inaugural iCMLf Forum: Saudi Arabia - Progress and Practice in CML brought together 43 physicians from across the Kingdom and beyond for a full day of evidence-based updates, debate, and clinical discussion in Riyadh. As our first iCMLf Forum delivered outside the United States, this meeting on November 1st 2025 marked an important milestone in strengthening global collaboration around CML management.
Led by Professors Jorge Cortes, Tim Hughes and Giuseppe Saglio, alongside an exceptional Saudi faculty including Professor Naeem Chaudhri, Dr Mohammed Almakadi, Dr Marwan Shaheen and Dr Binyam Usman, the Forum explored the latest science shaping CML management in 2025.
Session Summaries from the ESH-iCMLf 27th Annual John Goldman Conference on CML: Biology and Therapy
October 2025 - We're bringing you highlights from the recent ESH-iCMLf 27th Annual John Goldman Conference on CML: Biology and Therapy with a summary of selected scientific sessions.
🌟 Scientific Session: Stem Cells 🌟
Chair: Mary Scott (Glasgow)
This session explored new insights into leukemic stem cell biology, persistence, and the bone marrow microenvironment in CML. The speakers presented novel models and molecular mechanisms driving stem cell survival and relapse, highlighting inflammatory, metabolic, and stromal interactions shaping disease behaviour and treatment-free remission (TFR) potential.
Our key takeaways from the presentations:
